Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Demeo MK"'
Autor:
Freedman RA; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston. Electronic address: Rachel_freedman@dfci.harvard.edu., Heiling HM; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, USA., Li T; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, USA., Trapani D; Division of New Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan; Department of Oncology and Hematology, University of Milan, Milan, Italy., Tayob N; Medical Oncology, Dana-Farber Cancer Institute, Boston; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, USA., Smith KL; Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore., Davis R; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston., Pereslete AM; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston., DeMeo MK; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston., Cotter C; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston., Chen WY; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston., Parsons HA; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston., Santa-Maria CA; Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore., Van Poznak C; Department of Internal Medicine, University of Michigan, Ann Arbor., Moy B; Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston., Brufsky AM; Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh., Melisko ME; Division of Hematology and Oncology, University of California at San Francisco, San Francisco., O'Sullivan CC; Medical Oncology, Mayo Clinic, Rochester., Ashai N; Department of Medicine, Georgetown Lombardi Comprehensive Cancer Center and MedStar Health, Washington., Rauf Y; Department of Neurology, University of North Carolina, Chapel Hill., Nangia JR; Department of Medicine and Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston., Burns RT; Department of Medicine, Yale Cancer Center, New Haven, USA., Savoie J; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston., Wolff AC; Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore., Winer EP; Department of Medicine, Yale Cancer Center, New Haven, USA., Rimawi MF; Department of Medicine and Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston., Krop IE; Department of Medicine, Yale Cancer Center, New Haven, USA., Lin NU; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston.
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Nov; Vol. 35 (11), pp. 993-1002. Date of Electronic Publication: 2024 Jul 06.
Autor:
Grinshpun A; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston., Ren S; Department of Data Science, Dana-Farber Cancer Institute, Boston., Graham N; Department of Data Science, Dana-Farber Cancer Institute, Boston., DeMeo MK; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston., Wrabel E; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston., Carter J; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston., Tayob N; Harvard Medical School, Boston; Department of Data Science, Dana-Farber Cancer Institute, Boston., Pereslete A; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston., Hamilton E; Sarah Cannon Research Institute, Nashville; Breast and Gynecologic Research Program, Tennessee Oncology PLLC, Nashville., Juric D; Harvard Medical School, Boston; Massachusetts General Hospital Cancer Center, Boston, USA., Mayer EL; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston., Tolaney SM; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston., Krop IE; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston., Metzger O; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston. Electronic address: otto_metzger@dfci.harvard.edu.
Publikováno v:
ESMO open [ESMO Open] 2024 Jun; Vol. 9 (6), pp. 103465. Date of Electronic Publication: 2024 Jun 03.
Autor:
Filho OM; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Ian_Krop@dfci.harvard.edu michor@jimmy.harvard.edu Otto_Metzger@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., Viale G; Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy.; University of Milan, Milan, Italy., Stein S; Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Trippa L; Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Yardley DA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee., Mayer IA; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee., Abramson VG; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee., Arteaga CL; UT Southwestern Simmons Cancer Center, Dallas, Texas., Spring LM; Massachusetts General Hospital, Boston, Massachusetts., Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., Wrabel E; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., DeMeo MK; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., Bardia A; Massachusetts General Hospital, Boston, Massachusetts., Dell'Orto P; Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy., Russo L; Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy., King TA; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts., Polyak K; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Ludwig Center at Harvard, Boston, Massachusetts.; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, Massachusetts., Michor F; Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts. Ian_Krop@dfci.harvard.edu michor@jimmy.harvard.edu Otto_Metzger@dfci.harvard.edu.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Ludwig Center at Harvard, Boston, Massachusetts.; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts.; The Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Winer EP; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., Krop IE; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Ian_Krop@dfci.harvard.edu michor@jimmy.harvard.edu Otto_Metzger@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.
Publikováno v:
Cancer discovery [Cancer Discov] 2021 Oct; Vol. 11 (10), pp. 2474-2487. Date of Electronic Publication: 2021 May 03.
Autor:
Ruddy KJ; Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. ruddy.kathryn@mayo.edu., Zheng Y; Dana-Farber Cancer Institute, Boston, USA., Tayob N; Dana-Farber Cancer Institute, Boston, USA., Hu J; Dana-Farber Cancer Institute, Boston, USA., Dang CT; Memorial Sloan Kettering Cancer Center, New York, USA., Yardley DA; Tennessee Oncology, Nashville, USA., Isakoff SJ; Massachussetts General Hospital, Boston, USA., Valero VV; MD Anderson Cancer Center, Houston, USA., Faggen MG; Dana-Farber Cancer Institute, Boston, USA., Mulvey TM; Massachussetts General Hospital, Boston, USA., Bose R; Siteman Cancer Center, St. Louis, USA., Sella T; Dana-Farber Cancer Institute, Boston, USA., Weckstein DJ; New Hampshire Oncology and Hematology, Hooksett, USA., Wolff AC; Johns Hopkins University, Baltimore, USA., Reeder-Hayes KE; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA., Rugo HS; Diller Family Comprehensive Cancer Center, University of California San Francisco Helen, San Francisco, USA., Ramaswamy B; Ohio State University Comprehensive Cancer Center, Columbus, USA., Zuckerman DS; St. Luke's Mountain States Tumor Institute, Boise, USA., Hart LL; Florida Cancer Specialists, Brandon, USA., Gadi VK; University of Illinois At Chicago, Chicago, USA., Constantine M; Dana-Farber Cancer Institute, Boston, USA., Cheng KL; Northwell Health, New York, USA., Briccetti FM; Dana-Farber Cancer Institute, Boston, USA., Schneider BP; Indiana University School of Medicine, Indianapolis, USA., Merrill Garrett A; Eastern Maine Medical Center, Bangor, USA., Kelly Marcom P; Duke University, Durham, USA., Albain KS; Loyola University Medical Center, Maywood, USA., DeFusco PA; Hartford HealthCare Cancer Institute, Avon, USA., Tung NM; Beth Israel Deaconess Medical Center, Boston, USA., Ardman BM; Lowell General Hospital, Lowell, USA., Nanda R; University of Chicago, Chicago, USA., Jankowitz RC; Penn Medicine Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Rimawi M; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Abramson V; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Pohlmann PR; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Van Poznak C; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Forero-Torres A; Kirklin UAB Hematology Oncology, Birmingham, AL, USA., Liu MC; Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA., Rosenberg S; Dana-Farber Cancer Institute, Boston, USA., DeMeo MK; Dana-Farber Cancer Institute, Boston, USA., Burstein HJ; Dana-Farber Cancer Institute, Boston, USA., Winer EP; Dana-Farber Cancer Institute, Boston, USA., Krop IE; Dana-Farber Cancer Institute, Boston, USA., Partridge AH; Dana-Farber Cancer Institute, Boston, USA., Tolaney SM; Dana-Farber Cancer Institute, Boston, USA.
Publikováno v:
Breast cancer research and treatment [Breast Cancer Res Treat] 2021 Aug; Vol. 189 (1), pp. 103-110. Date of Electronic Publication: 2021 Jun 12.
Autor:
Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, Duda DG
Publikováno v:
The oncologist [Oncologist] 2021 Aug; Vol. 26 (8), pp. e1483. Date of Electronic Publication: 2021 May 12.
Autor:
Tolaney SM; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Ziehr DR; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Guo H; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Ng MR; Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital Research Institute, Boston, Massachusetts, USA., Barry WT; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Higgins MJ; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Isakoff SJ; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Brock JE; Brigham and Women's Hospital, Boston, Massachusetts, USA., Ivanova EV; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Paweletz CP; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Demeo MK; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Ramaiya NH; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Overmoyer BA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Jain RK; Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital Research Institute, Boston, Massachusetts, USA., Winer EP; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Duda DG; Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital Research Institute, Boston, Massachusetts, USA.
Publikováno v:
The oncologist [Oncologist] 2017 Jan; Vol. 22 (1), pp. 25-32. Date of Electronic Publication: 2016 Oct 27.